Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Total net revenue		$ 101,132	$ 118,060	$ 312,262	$ 329,313
Total cost of revenue	[1]	72,058	79,342	207,793	213,031
Research and development	[2]	10,909	14,209	40,203	42,942
Products
Total net revenue	[3]	49,603	62,846	154,491	170,738
Total cost of revenue		35,945	43,529	105,977	111,627
Services
Total net revenue	[4]	51,529	55,214	157,771	158,575
Total cost of revenue		36,113	35,813	101,816	101,404
Revenue from Joint Venture
Total cost of revenue		13,887	13,905	40,260	29,728
Research and development		0	97	199	1,363
Revenue from Joint Venture | Products
Total net revenue		15,662	18,118	55,504	43,702
Revenue from Joint Venture | Services
Total net revenue		$ 3,982	$ 2,696	$ 10,970	$ 8,147

[1] Includes cost of revenue from sales to the joint venture, an equity method investment, of $13,887 and $40,260 during the three and nine months ended March 31, 2024 and $13,905 and $29,728 during the three and nine months ended March 31, 2023, respectively.

[2] Includes charge backs to the joint venture, an equity method investment, related to research and development of $199 during the nine months ended March 31, 2024, and $97 and $1,363 during the three and nine months ended March 31, 2023, respectively. There were no charge backs to the joint venture related to research and development during the three months ended March 31, 2024.

[3] Includes sales of products to the joint venture, an equity method investment, of $15,662 and $55,504 during the three and nine months ended March 31, 2024 and $18,118 and $43,702 during the three and nine months ended March 31, 2023, respectively. See Note 13.

[4] Includes sales of services to the joint venture, an equity method investment, of $3,982 and $10,970 during the three and nine months ended March 31, 2024 and $2,696 and $8,147 during the three and nine months ended March 31, 2023, respectively. See Note 13.